Novartis Malaria Drug Kills Bugs at Earliest Stage, Study Shows

Novartis AG developed a new class of experimental malaria drugs, its second in 14 months, advancing the search for treatments to replace current medicines as they lose potency against the infectious killer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.